ArticleBioactive materials2027
A bioactivity-enhanced thermosensitive amnion-derived hydrogel with sustained IGF-1 release: A multitargeted and efficient strategy for corneal injury repair.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal alkali burn (CAB) remains difficult to treat because rapid tear clearance limits topical drug exposure, while the injured cornea develops a complex microenvironment involving inflammation, neovascularization, fibrosis, epithelial barrier loss, and impaired nerve repair. Here, we developed a human amniotic membrane-derived thermosensitive hydrogel (hAMgel) and loaded it with insulin-like growth factor-1 (IGF-1) to create a bioactive sustained-release system (IGF1@hAMgel) for CAB repair. The hAMgel transformed from a flowable precursor into a semi-transparent film on the ocular surface within 1-2 min and IGF1@hAMgel released approximately 90% of loaded IGF-1 over 24 h, with corneal IGF-1 concentration peaking at 2 h post-dose (378.5 pg/mg protein) and remaining detectable over 24 h, supporting sustained topical exposure. In a rat CAB model, IGF1@hAMgel accelerated epithelial healing, reducing the fluorescein-stained area from 31.34 ± 2.83% in controls to 16.78 ± 2.87% at day 1. By day 14, IGF1@hAMgel reduced corneal opacity (0.67 ± 0.52 vs. 4.00 ± 0.00), resolved edema with central corneal thickness approaching baseline (187.7 ± 16.31 μm vs. 178.3 ± 5.89 μm), suppressed neovascularization (CD31-positive area 4.46 ± 1.69% vs. 24.33 ± 2.07%), and promoted corneal nerve regeneration. Proteomic analysis showed that hAMgel retained abundant extracellular matrix(ECM) components, including collagens, Lumican, and fibronectin, together with repair-related and immunomodulatory proteins. These findings identify IGF1@hAMgel as a sutureless, eye-drop-like bioactive ECM platform that integrates growth-factor delivery with amnion-derived reparative cues for multitargeted ocular surface repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.